Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsGlycopeptide resistance in gram-positive cocci: a review.Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.
P2860
Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Intact mutS in laboratory-deri ...... Staphylococcus aureus strains
@ast
Intact mutS in laboratory-deri ...... Staphylococcus aureus strains
@en
type
label
Intact mutS in laboratory-deri ...... Staphylococcus aureus strains
@ast
Intact mutS in laboratory-deri ...... Staphylococcus aureus strains
@en
prefLabel
Intact mutS in laboratory-deri ...... Staphylococcus aureus strains
@ast
Intact mutS in laboratory-deri ...... Staphylococcus aureus strains
@en
P2093
P2860
P1476
Intact mutS in laboratory-deri ...... Staphylococcus aureus strains
@en
P2093
Arunachalam Muthaiyan
Brian J Wilkinson
Radheshyam K Jayaswal
P2860
P304
P356
10.1128/AAC.48.2.623-625.2004
P407
P577
2004-02-01T00:00:00Z